Lung Cancer | Oncology Today with Dr Neil Love: Predictors of Response to Cancer Immunotherapy

Research To Practice | Oncology Videos

Featuring an interview with Prof Solange Peters on the following topics:

• Emerging biomarkers for predicting response to cancer immunotherapy (0:00)
• Case: A man in his late 50s with metastatic pleomorphic carcinoma of the lung and a high tumor mutational burden (TMB) attains a complete response to pembrolizumab (25:43)
• Role of TMB in determining response to immune checkpoint inhibitors; FDA approval of pembrolizumab for TMB-high (≥10 mut/Mb) solid tumors and implications for clinical practice (29:48)
• Assessment of TMB as a biomarker for use of immunotherapy; variation of TMB over time (34:40)
• Correlation between TMB or PD-L1 level and smoking status; role of POLE mutations and the STING pathway in the immune response (38:51)
• Rationale for the investigation of PARP inhibitors in combination with immunotherapy (43:04)
• Efficacy of cemiplimab versus chemotherapy for PD-L1-high advanced non-small cell lung cancer (NSCLC) (47:25)
• Diversity of the gut microbiome as a potential predictor of response to immune checkpoint inhibitors (49:42)
• Effect of PD-1/PD-L1 expression on the immune response; assays for the assessment of PD-L1 status (55:05)
• Activity of the anti-TIGIT antibody tiragolumab in combination with atezolizumab for PD-L1-high advanced NSCLC; potential role of neoantigen burden as a predictor of response to immunotherapy (59:04)
• Consideration of the benefits and risks of immunotherapy for cancer (1:08:24)

CME information and select publications